Highly active MEGACD40L® oligomer mimics in vivo membrane-assisted CD40L aggregation and stimulation without the need for enhancers
High purity with low endotoxin levels
Experienced manufacturing results in consistent and dependable lot-to-lot performance
Optimized formulation for improved stability and enhanced activity
MEGACD40L® is a high activity protein in which two trimeric CD40 ligand molecules are artificially linked via the collagen domain of Adiponectin/ACRP30/AdipoQ. This protein very effectively simulates the natural membrane-assisted aggregation of CD40L in vivo. It provides a simple and equally potent alternative to [CD40L+enhancer] combinations (Prod. No. ALX-850-064).
Product Details
| Alternative Name: | CD40L:ACRP30headless, CD154:ACRP30headless, TNFSF 5:ACRP30headless, gp39:ACRP30headless |
|
| MW: | ~38kDa |
|
| Source: | Produced in CHO cells. The extracellular domain of human CD40L (CD154) (aa 116-261) is fused at the N-terminus to mouse ACRP30headless (aa 18-111) and a FLAG®-tag. |
|
| UniProt ID: | P29965 (human CD40L), Q60994 (mouse Adiponectin) |
|
| Concentration: | 0.1mg/ml after reconstitution. |
|
| Formulation: | Lyophilized. Contains PBS. |
|
| Purity: | ≥90% (SDS-PAGE) |
|
| Purity Detail: | Purified by multi-step chromatography. |
|
| Endotoxin Content: | ≤0.01EU/µg purified protein (LAL test; Cape Cod Associates). |
|
| Biological Activity: | Binds to human CD40. Induces B cells activation (as demonstrated by dose-dependent upregulation of CD86). |
|
| Application Notes: | Can be used to mediate immune and inflammatory responses, as a protein tool for pre-clinical studies in immunotherapy, to monitor patients undergoing chemotherapy and to mimic autoimmune phenotypes in vivo. |
|
| Reconstitution: | Reconstitute with 100µl sterile water. Further dilutions should be made with medium containing 5% fetal calf serum. |
|
| Shipping: | Shipped on Blue Ice |
|
| Long Term Storage: | -20°C |
|
| Use/Stability: | Stable for at least 6 months after receipt when stored at -20°C. |
|
| Handling: | Avoid freeze/thaw cycles. After reconstitution, prepare aliquots and store at -20°C. |
|
| Technical Info/Product Notes: | FLAG is a registered trademark of Sigma-Aldrich Co. |
|
| Regulatory Status: | RUO - Research Use Only |
|
B cell lymphocyte activation by MEGACD40L® (Prod. No. ALX-522-110). Method: Peripheral Blood Mononuclear Cells (PBMCs) were incubated at 37°C, 5% CO2 for 48 hours in 48 well plates (1 x 106 cells/well). Each well contained 200µl serum free test media with serially diluted MEGACD40L®. After treatment, cells were washed and dual-stained with mouse anti-human CD19–PE and mouse anti-human CD86–APC and analyzed by flow cytometry. The data are presented as the percent of CD19 positive B cells that co-stain as CD86 positive, at each concentration of MEGACD40L®.
Please mouse over
Product Literature References
Inverse Regulation of Confluence-Dependent ADAMTS13 and von Willebrand Factor Expression in Human Endothelial Cells: M. Popa, et al.; Thromb. Haemost. (2021), Abstract;
Quantitative assessment of NFκB transcription factor activity: T.J. Hunter, et al.; J. Immunol. Methods 2021, 112954 (2021), Abstract;
Renal Fibrosis Is Significantly Attenuated Following Targeted Disruption of Cd40 in Experimental Renal Ischemia: S. Zhang, et al.; J. Am. Heart Assoc. 9, e014072 (2020), Abstract; Full Text
C1s Inhibition by BIVV009 (Sutimlimab) Prevents Complement-Enhanced Activation of Autoimmune Human B Cells In Vitro: P.A. Nikitin, et al.; J. Immunol. 202, 1200 (2019), Abstract; Full Text
CRISPR/Cas9 Screens Reveal Multiple Layers of B cell CD40 Regulation: C. Jiang, et al.; Cell Rep. 28, 1307 (2019), Abstract; Full Text
Epstein-Barr-Virus-Induced One-Carbon Metabolism Drives B Cell Transformation: L.W. Wang, et al.; Cell Metab. 30, 539 (2019), Abstract; Full Text
Type 1-programmed dendritic cells drive antigen-specific latency reversal and immune elimination of persistent HIV-1: J. Kristoff, et al.; EBioMedicine 43, 295 (2019), Abstract; Full Text
CD40L and TNF both activate the classical NF-κB pathway, which is not required for the CD40L induced alternative pathway in endothelial cells: J. Seigner, et al.; Biochem. Biophys. Res. Commun. 495, 1389 (2018), Abstract;
CD40L mediated alternative NFκB-signaling induces resistance to BCR-inhibitors in patients with mantle cell lymphoma: H. Rauert-Wunderlich, et al.; Cell Death Dis. 9, 86 (2018), Abstract; Full Text
Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus: J.M. Riggs, et al.; Lupus Sci. Med. 5, e000261 (2018), Abstract; Full Text
Engineering protein-secreting plasma cells by homology-directed repair in primary human B cells: K.L. Hung, et al.; Mol. Ther. 26, 456 (2018), Abstract;
High PD-L1/CD86 MFI ratio and IL-10 secretion characterize human regulatory dendritic cells generated for clinical testing in organ transplantation: A.F. Zahorchak, et al.; Cell. Immunol. 323, 9 (2018), Abstract;
In vitro antineoplastic effects of auranofin in canine lymphoma cells: H. Zhang, et al.; BMC Cancer 18, 522 (2018), Abstract; Full Text
Arginine methylation catalyzed by PRMT1 is required for B cell activation and differentiation: S. Infantino, et al.; Nat. Commun. 8, 891 (2017), Application(s): B-cell activation, Abstract; Full Text
B-cell activation with CD40L or CpG measures the function of B-cell subsets and identifies specific defects in immunodeficient patients: E. Marasco, et al.; Eur. J. Immunol. 47, 131 (2017), Application(s): Human PBMC culture, Abstract; Full Text
CD40 signaling in Graves disease is mediated through canonical and noncanonical thyroidal nuclear factor κB activation: H.J. Lee, et al.; Endocrinology 158, 410 (2017), Abstract; Full Text
如需购买或咨询该产品技术问题，请联系ENZO一级代理商-欣博盛生物
在线咨询
电话咨询
